AuricX Pharmaceuticals

AuricX Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing innovative therapies for the prevention and treatment of serious infectious diseases. The company's primary focus is on addressing the global threat of antimicrobial resistance, specifically targeting Staphylococcus aureus (S. aureus) and its methicillin-resistant strains (MRSA). Its lead candidate, ACX-31, is a topical small molecule designed for nasal decolonization to reduce the risk of surgical site infections in high-risk patients. Developed based on research from the University of Houston, ACX-31 offers a novel mechanism of action compared to existing antibiotics. AuricX aims to improve clinical outcomes in hospital settings by providing more effective tools for infection control.